Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

@article{Dombernowsky1998LetrozoleAN,
  title={Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.},
  author={Per Dombernowsky and I Quah Smith and Geoffrey Falkson and Robert D. Leonard and Lawrence Panasci and Joaquim Bellmunt and Werner Robert Bezwoda and Giovanni Gardin and A. C. Gudgeon and Michael N. Morgan and Adriano Fornasiero and Wolfgang Hoffmann and J Michel and Thomas Hatschek and T Tjabbes and H A Chaudri and Ulrike Hornberger and Patrick Trunet},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 2},
  pages={453-61}
}
PURPOSE To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens. PATIENTS AND METHODS Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2.5 mg (n = 174), letrozole 0.5 mg (n = 188), or MA 160 mg (n = 189) once daily in a double-blind, multicenter trial. Data were analyzed for… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 188 extracted citations

Role of aromatase inhibitors in advanced breast cancer.

Endocrine-related cancer • 1999
View 4 Excerpts
Highly Influenced

Cross-resistance to different aromatase inhibitors in breast cancer treatment.

Endocrine-related cancer • 1999
View 4 Excerpts
Highly Influenced

Use of aromatase inhibitors in breast carcinoma.

Endocrine-related cancer • 1999
View 4 Excerpts
Highly Influenced

Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2001
View 8 Excerpts
Highly Influenced

Are differences in the available aromatase inhibitors and inactivators significant?

Clinical cancer research : an official journal of the American Association for Cancer Research • 2001
View 4 Excerpts
Highly Influenced

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1999
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…